Seek Returns

AMGN vs. ZTS: Amgen vs. Zoetis Stock Comparison

How do Amgen (AMGN) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Amgen (AMGN) and Zoetis (ZTS)
Profile ItemAMGNZTS
NameAmgen Inc. Common StockZoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization249.05 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 17, 1983February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
ZTS
GSPC
Loading price history…
Amgen (AMGN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Total Return (1Y)48.82%-30.10%
Total Return (3Y, Annualized)24.31%-20.42%
Total Return (5Y, Annualized)20.67%-16.87%

Risk Profile

Drawdown History

AMGN
ZTS
GSPC
Loading price history…
Amgen (AMGN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Volatility (1Y, Annualized)29.12%38.23%
Beta (5Y)0.430.66
Max Drawdown (5Y)-24.86%-70.45%
Avg. Volume (3M)2.76M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Sharpe Ratio (1Y)1.53-0.90
Sortino Ratio (1Y)2.36-1.10

Profitability

ROE (TTM)

Both Amgen (AMGN) at 78.35% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 24.14% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
ROE (TTM)78.35%57.63%
ROA (TTM)8.91%14.87%
Net Margin (TTM)24.14%26.41%
Operating Margin (TTM)35.79%38.19%
Gross Margin (TTM)72.47%71.65%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Zoetis (ZTS) at 10.05% is closer to the peer norm — faster per-share earnings growth for AMGN.

Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Revenue Growth (YoY)9.95%2.28%
Revenue Growth (3Y CAGR)11.77%5.42%
EPS Growth (YoY)88.23%10.05%
EPS Growth (3Y CAGR)5.52%10.27%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both Amgen (AMGN) at 3.76 and Zoetis (ZTS) at 2.80 — each debt-to-equity ratio is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Current Ratio (MRQ)1.482.35
Debt / Equity (MRQ)3.762.80
Net Debt / EBITDA2.311.92

Dividends

Dividend Yield (TTM)

Both Amgen (AMGN) at 2.16% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Amgen (AMGN) at 57.62% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
Dividend Yield (TTM)2.16%2.55%
Dividend Payout Ratio (TTM)57.62%35.24%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Zoetis (ZTS) at 9.80 sits in the upper P/B ratio quartile, and Amgen (AMGN) at 17.35 prices even higher, above its industry range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Zoetis (ZTS)
MetricAMGNZTS
P/E Ratio (TTM)26.6913.50
P/S Ratio (TTM)6.403.40
P/B Ratio (MRQ)17.359.80
Free Cash Flow Yield (TTM)2.96%6.36%